Finance

Lists
540222:BOM
Laurus Labs Ltd
₹1,935.20
+3.58%
(+66.95) 1D
Sep 8, 12:12:42 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 540222...
Open
₹1,872.70
High
₹1,940.25
Low
₹1,865.00
Mkt. cap
1.04T
Avg. vol.
0.00
Volume
34.38K
Dividend
0.10%
Quarterly dividend
₹0.50
Ex-dividend date
May 8, 2026
P/E ratio
95.68
52-wk high
₹1,947.90
52-wk low
₹822.85
EPS
₹20.23
Shares outstanding
106.44M
No. of employees
7K
Open
₹1,872.70
High
₹1,940.25
Low
₹1,865.00
Mkt. cap
1.04T
Avg. vol.
0.00
Volume
34.38K
Dividend
0.10%
Quarterly dividend
₹0.50
Ex-dividend date
May 8, 2026
P/E ratio
95.68
52-wk high
₹1,947.90
52-wk low
₹822.85
EPS
₹20.23
Shares outstanding
106.44M
No. of employees
7K
Profile
Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients, generic formulations, custom synthesis, biotechnology, veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava. Laurus Labs has its eight manufacturing plants located at Visakhapatnam, Hyderabad and Bangalore. The manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA. The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers. The R&D centres are based in Hyderabad, Visakhapatnam and United States. Wikipedia
About Laurus Labs Ltd
CEOSatyanarayana Chava
Employees7.06K
Founded2005
Headquarters-
SectorPharmaceutical industry
Websitelauruslabs.com
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
16.53B
17.78B
18.12B
20.26B
Cost of goods sold
6.63B
6.95B
8.34B
7.56B
Cost of revenue
6.63B
6.95B
8.34B
7.56B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.16B
2.29B
2.57B
2.59B
Operating expense
7.07B
7.24B
5.86B
7.56B
Total operating expenses
13.71B
14.19B
14.20B
15.12B
Operating income
2.83B
3.60B
3.92B
5.14B
Other non operating income
269.60M
57.60M
-330.90M
91.80M
EBT including unusual items
2.70B
3.25B
3.62B
4.81B
EBT excluding unusual items
2.70B
3.25B
3.62B
4.81B
Income tax expense
759.80M
734.50M
794.60M
1.19B
Effective tax rate
28.09%
22.58%
21.98%
24.79%
Other operating expenses
3.71B
3.74B
2.07B
3.73B
Net income
1.95B
2.52B
2.79B
3.68B
Net profit margin
11.79%
14.15%
15.41%
18.14%
Earnings per share
3.61
4.65
5.17
6.80
Interest and investment income
-
-
65.70M
-
Interest expense
-400.00M
-387.90M
-307.60M
-422.20M
Net interest expenses
-400.00M
-387.90M
-241.90M
-422.20M
Depreciation and amortization charges
1.20B
1.21B
1.22B
1.24B
EBITDA
4.01B
4.62B
5.12B
6.34B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps